Advanced searchCitation search
Skip main navigation
Close Drawer MenuOpen Drawer Menu
Reviews18 July 2006

Narrative Review: A Rational Approach to Starting Insulin Therapy

    Author, Article, and Disclosure Information
    https://doi.org/10.7326/0003-4819-145-2-200607180-00010
    Background:

    The emergence of multiple insulin products has provided new opportunities to achieve diabetes control. However, the number of options has raised concerns about the optimal choices of products.

    Purpose:

    To briefly review the pharmacologic characteristics of currently available insulin products and to suggest an initial insulin regimen based on common blood glucose profiles among patients with diabetes.

    Data Sources:

    Relevant manuscripts were identified through a MEDLINE search (1996 to 25 February 2006) of the English-language literature. The key phrase used was therapeutic use ofinsulin. The literature search was limited to core clinical journals that have accessible full texts.

    Study Selection:

    Clinical trials and authoritative reviews published between 1996 and February 2006 were selected. A total of 420 manuscripts was reviewed.

    Data Extraction:

    The authors independently reviewed the relevant available literature. This literature, along with the authors' clinical experience, was used to construct practical suggestions.

    Data Synthesis:

    Several new insulin and insulin analogue preparations are now available for clinical use. Used as prandial insulin (for example, insulin lispro, insulin aspart, or insulin glulisine) and basal insulin (for example, insulin glargine or insulin detemir), the analogues simulate physiologic insulin profiles more closely than the older conventional insulins. There is currently no strong rationale favoring glargine, neutral protamine Hagedorn insulin, insulin detemir, or fixed-ratio insulin preparations as the preferred agent for initiating insulin therapy.

    Limitations:

    This was a retrospective review of previously published manuscripts chosen at the authors' discretion.

    Conclusions:

    The advent of recombinant DNA technology made it possible to overcome limitations in the time-action profiles of conventional insulins. Insulin therapy must be individualized. Nevertheless, certain subgroups of patients with diabetes can be differentiated from each other according to the pattern of blood glucose changes during the day. On the basis of the blood glucose profile, the authors suggest an initial insulin regimen that can be used to evaluate individual responsiveness and plan a long-term regimen.

    References

    • 1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977-86. [PMID: 8366922] CrossrefMedlineGoogle Scholar
    • 2. Oiknine R, Bernbaum M, Mooradian AD. A critical appraisal of the role of insulin analogues in the management of diabetes mellitus. Drugs. 2005;65:325-40. [PMID: 15669878] CrossrefMedlineGoogle Scholar
    • 3. Riddle MC. Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations. Endocrinol Metab Clin North Am. 2005;34:77-98. [PMID: 15752923] CrossrefMedlineGoogle Scholar
    • 4. Wang F, Carabino JM, Vergara CM. Insulin glargine: a systematic review of a long-acting insulin analogue. Clin Ther. 2003;25:1541-77. [PMID: 12860485] CrossrefMedlineGoogle Scholar
    • 5. Gerich JE. Novel insulins: expanding options in diabetes management. Am J Med. 2002;113:308-16. [PMID: 12361817] CrossrefMedlineGoogle Scholar
    • 6. Vajo Z, Fawcett J, Duckworth WC. Recombinant DNA technology in the treatment of diabetes: insulin analogs. Endocr Rev. 2001;22:706-17. [PMID: 11588149] CrossrefMedlineGoogle Scholar
    • 7. Dunn CJ, Plosker GL, Keating GM, McKeage K, Scott LJ. Insulin glargine: an updated review of its use in the management of diabetes mellitus. Drugs. 2003;63:1743-78. [PMID: 12904090] CrossrefMedlineGoogle Scholar
    • 8. Chapman TM, Noble S, Goa KL. Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus. Drugs. 2002;62:1945-81. [PMID: 12215068] CrossrefMedlineGoogle Scholar
    • 9. McKeage K, Goa KL. Insulin glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus. Drugs. 2001;61:1599-624. [PMID: 11577797] CrossrefMedlineGoogle Scholar
    • 10. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes. 1994;43:396-402. [PMID: 8314011] CrossrefMedlineGoogle Scholar
    • 11. Simpson KL, Spencer CM. Insulin aspart. Drugs. 1999;57:759-67. [PMID: 10353301] CrossrefMedlineGoogle Scholar
    • 12. Barlocco D. Insulin glulisine. Aventis Pharma. Curr Opin Investig Drugs. 2003;4:1240-4. [PMID: 14649217] MedlineGoogle Scholar
    • 13. Ristic S, Bates PC. Effects of rapid-acting insulin analogs on overall glycemic control in type 1 and type 2 diabetes mellitus. Diabetes Technol Ther. 2003;5:57-66. [PMID: 12725708] CrossrefMedlineGoogle Scholar
    • 14. Rami B, Schober E. Postprandial glycaemia after regular and lispro insulin in children and adolescents with diabetes. Eur J Pediatr. 1997;156:838-40. [PMID: 9392394] CrossrefMedlineGoogle Scholar
    • 15. Rutledge KS, Chase HP, Klingensmith GJ, Walravens PA, Slover RH, Garg SK. Effectiveness of postprandial Humalog in toddlers with diabetes. Pediatrics. 1997;100:968-72. [PMID: 9374566] CrossrefMedlineGoogle Scholar
    • 16. Gerich JE. Insulin glargine: long-acting basal insulin analog for improved metabolic control. Curr Med Res Opin. 2004;20:31-7. [PMID: 14741069] CrossrefMedlineGoogle Scholar
    • 17. Hamann A, Matthaei S, Rosak C, Silvestre L. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes. Diabetes Care. 2003;26:1738-44. [PMID: 12766103] CrossrefMedlineGoogle Scholar
    • 18. Yki-Järvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care. 2000;23:1130-6. [PMID: 10937510] CrossrefMedlineGoogle Scholar
    • 19. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080-6. [PMID: 14578243] CrossrefMedlineGoogle Scholar
    • 20. Heinemann L, Sinha K, Weyer C, Loftager M, Hirschberger S, Heise T. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Diabet Med. 1999;16:332-8. [PMID: 10220208] CrossrefMedlineGoogle Scholar
    • 21. Markussen J, Havelund S, Kurtzhals P, Andersen AS, Halstrøm J, Hasselager E, et al. Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia. 1996;39:281-8. [PMID: 8721773] CrossrefMedlineGoogle Scholar
    • 22. Kurtzhals P, Havelund S, Jonassen I, Kiehr B, Ribel U, Markussen J. Albumin binding and time action of acylated insulins in various species. J Pharm Sci. 1996;85:304-8. [PMID: 8699334] CrossrefMedlineGoogle Scholar
    • 23. Plank J, Bodenlenz M, Sinner F, Magnes C, Görzer E, Regittnig W, et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care. 2005;28:1107-12. [PMID: 15855574] CrossrefMedlineGoogle Scholar
    • 24. Heise T, Weyer C, Serwas A, Heinrichs S, Osinga J, Roach P, et al. Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin. Diabetes Care. 1998;21:800-3. [PMID: 9589244] CrossrefMedlineGoogle Scholar
    • 25. Bott U, Ebrahim S, Hirschberger S, Skovlund SE. Effect of the rapid-acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with Type 1 diabetes. Diabet Med. 2003;20:626-34. [PMID: 12873289] CrossrefMedlineGoogle Scholar
    • 26. Buse JB, Polonsky KS, Burant CF. Type 2 diabetes mellitus.. In: Larsen PR, Kronenberg HM, Melmed S, Polonksy KS, eds. Williams Textbook of Endocrinology. 10th ed. Philadelphia: Elsevier Science; 2003:1441-2. Google Scholar
    • 27. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002;287:360-72. [PMID: 11790216] CrossrefMedlineGoogle Scholar
    • 28. Chehade JM, Mooradian AD. A rational approach to drug therapy of type 2 diabetes mellitus. Drugs. 2000;60:95-113. [PMID: 10929931] CrossrefMedlineGoogle Scholar
    • 29. Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA, et al. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;128:176-85. [PMID: 9454525] LinkGoogle Scholar
    • 30. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non–insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995;333:541-9. [PMID: 7623902] CrossrefMedlineGoogle Scholar
    • 31. Mooradian AD, Thurman JE. Drug therapy of postprandial hyperglycaemia. Drugs. 1999;57:19-29. [PMID: 9951949] CrossrefMedlineGoogle Scholar
    • 32. American Diabetes Association. Postprandial blood glucose. Diabetes Care. 2001;24:775-8. [PMID: 11315848] CrossrefMedlineGoogle Scholar
    • 33. Riddle MC, Drucker DJ. Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. Diabetes Care. 2006;29:435-49. [PMID: 16443905] CrossrefMedlineGoogle Scholar
    • 34. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest. 1999;104:787-94. [PMID: 10491414] CrossrefMedlineGoogle Scholar
    • 35. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131:281-303. [PMID: 10454950] LinkGoogle Scholar
    • 36. Clement S, Braithwaite SS, Magee MF, Ahmann A, Smith EP, Schafer RG, et al. Management of diabetes and hyperglycemia in hospitals. Diabetes Care. 2004;27:553-91. [PMID: 14747243] CrossrefMedlineGoogle Scholar
    • 37. Trence DL, Kelly JL, Hirsch IB. The rationale and management of hyperglycemia for in-patients with cardiovascular disease: time for change. J Clin Endocrinol Metab. 2003;88:2430-7. [PMID: 12788838] CrossrefMedlineGoogle Scholar
    • 38. Retnakaran R, Hochman J, DeVries JH, Hanaire-Broutin H, Heine RJ, Melki V, et al. Continuous subcutaneous insulin infusion versus multiple daily injections: the impact of baseline A1c. Diabetes Care. 2004;27:2590-6. [PMID: 15504991] CrossrefMedlineGoogle Scholar
    • 39. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ. 2002;324:705. [PMID: 11909787] CrossrefMedlineGoogle Scholar
    • 40. Oiknine R, Mooradian AD. Drug therapy of diabetes in the elderly. Biomed Pharmacother. 2003;57:231-9. [PMID: 12888259] CrossrefMedlineGoogle Scholar
    • 41. Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28:260-5. [PMID: 15677776] CrossrefMedlineGoogle Scholar
    • 42. UKHealth Care. UK insulin protocols. Accessed at www.mc.uky.edu/pharmacy/dic/criteria/UKinsulinprotocols.pdf on 30 May 2006. Google Scholar
    • 43. Making bolus insulin changes. Accessed at www.bddiabetes.com/us/download/insulin_adjustment_workbook_section3.pdf on 30 May 2006. Google Scholar
    • 44. Roach P, Yue L, Arora V. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Humalog Mix25 Study Group. Diabetes Care. 1999;22:1258-61. [PMID: 10480767] CrossrefMedlineGoogle Scholar
    • 45. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Järvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care. 2005;28:254-9. [PMID: 15677775] CrossrefMedlineGoogle Scholar
    • 46. Malone JK, Kerr LF, Campaigne BN, Sachson RA, Holcombe JH. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther. 2004;26:2034-44. [PMID: 15823767] CrossrefMedlineGoogle Scholar
    • 47. Garg SK, Frias JP, Anil S, Gottlieb PA, MacKenzie T, Jackson WE. Insulin lispro therapy in pregnancies complicated by type 1 diabetes: glycemic control and maternal and fetal outcomes. Endocr Pract. 2003;9:187-93. [PMID: 12917059] CrossrefMedlineGoogle Scholar
    • 48. Pettitt DJ, Ospina P, Kolaczynski JW, Jovanovic L. Comparison of an insulin analog, insulin aspart, and regular human insulin with no insulin in gestational diabetes mellitus. Diabetes Care. 2003;26:183-6. [PMID: 12502678] CrossrefMedlineGoogle Scholar
    • 49. Gamson K, Chia S, Jovanovic L. The safety and efficacy of insulin analogs in pregnancy. J Matern Fetal Neonatal Med. 2004;15:26-34. [PMID: 15101608] CrossrefMedlineGoogle Scholar
    • 50. Edelman SV, Morello CM. Strategies for insulin therapy in type 2 diabetes. South Med J. 2005;98:363-71. [PMID: 15813164] CrossrefMedlineGoogle Scholar
    • 51. American Diabetes Association. Standards of Medical Care in Diabetes-2006. Diabetes Care. 2006;29 SUPPL 1 S4-S42. [PMID: 16373931] MedlineGoogle Scholar
    • 52. Metzger BE, Coustan DR. Summary and recommendations of the Fourth International Workshop-Conference on Gestational Diabetes Mellitus. The Organizing Committee. Diabetes Care. 1998;21 SUPPL 2 B161-7. [PMID: 9704245] MedlineGoogle Scholar
    • 53. American Diabetes Association. Gestational diabetes mellitus. Diabetes Care. 2004;27 SUPPL. 1 S88-S90. [PMID: 14693936] CrossrefMedlineGoogle Scholar
    • 54. Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 2002;48:436-72. [PMID: 11861436] CrossrefMedlineGoogle Scholar
    Previous
    Next

    Submit a Comment

    Contributors must reveal any conflict of interest. Comments are moderated. Please see our information for authorsregarding comments on an Annals publication.
    *All comments submitted after October 1, 2021 and selected for publication will be published online only.
    Cancel